In accord with ASX requirements, Imagion Biosystems’ 2017 quarterly update was lodged with the Australian Securities Exchange on 31 January 2018. The update includes Appendix 4C and commentary on the Company’s progress toward the first in-human clinical studies of its proprietary MagSense® technology.
View Imagion Biosystems December 2017 Quarterly Update.
Join Us at RSNA and SABCS: Advancing Molecular MRI for Cancer Detection
November 13, 2025
We are excited to announce that Imagion Biosystems (ASX: IBX) will be attending two premier medical conferences this fall: the Radiological Society of North